QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.081570v1 313/2/814    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pitarque, M. Articles by Ingelman-Sundberg, M. Search for Related Content PubMed PubMed Citation Articles by Pitarque, M. Articles by Ingelman-Sundberg, M.

CELLULAR AND MOLECULAR

Transcriptional Regulation of the Human CYP2A6 Gene

Institute of Environmental Medicine, Division of Molecular Toxicology, Karolinska Institutet, Stockholm, Sweden

Nicotine C-oxidation is primarily catalyzed by CYP2A6 in humans. This enzymatic activity exhibits a large interindividual variability, which to a great extent is caused by genetic polymorphisms in the CYP2A6 gene. There are large interindividual differences in CYP2A6 mRNA and protein levels, but little is known about the transcriptional regulation of CYP2A6, which can, e.g., explain such differences. Using transient transfections of 5'-deleted CYP2A6 promoter constructs in human hepatoma B16A2 cells, we show that maximal promoter activity was harbored in the sequence spanning from –112 to –61. Putative response elements for the transcription factors hepatocyte nuclear factor-4 (HNF-4), CCAAT-box/enhancer binding protein (C/EBP), C/EBP, and octamer transcription factor-1 (Oct-1) were identified in this region, and electrophoretic mobility shift assays showed that these transcription factors bind to the predicted elements. To determine the relevance of these sites, expression vectors for these transcription factors were cotransfected with CYP2A6 promoter constructs in HepG2 cells. HNF-4, C/EBP, and Oct-1 exerted an activating effect, whereas overexpression of C/EBP reduced CYP2A6 promoter activity. To confirm the importance of these sites in vivo, mutated CYP2A6 reporter constructs were injected into mouse liver. Mutation of either HNF-4 or C/EBP-Oct-1 motifs significantly decreased promoter activity, 52 and 26% of wildtype, respectively, whereas when both motifs were mutated the activity in mice decreased to 14% of wild type. In conclusion, the data indicate that the constitutive hepatic expression of CYP2A6 is governed by an interplay between the transcription factors HNF-4, C/EBP, C/EBP, and Oct-1. These results will be important for the identification of new polymorphisms affecting CYP2A6 gene expression.

Address correspondence to: Dr. Cristina Rodriguez-Antona, Karolinska Institutet, Institute of Environmental Medicine, Division of Molecular Toxicology, Nobels väg 13, 17177 Stockholm, Sweden. E-mail: cristina.rodriguezantona{at}imm.ki.se

This article has been cited by other articles:

				T. Onica, K. Nichols, M. Larin, L. Ng, A. Maslen, Z. Dvorak, J.-M. Pascussi, M.-J. Vilarem, P. Maurel, and G. M. Kirby Dexamethasone-Mediated Up-Regulation of Human CYP2A6 Involves the Glucocorticoid Receptor and Increased Binding of Hepatic Nuclear Factor 4{alpha} to the Proximal Promoter Mol. Pharmacol., February 1, 2008; 73(2): 451 - 460. [Abstract] [Full Text] [PDF]

				G. Siest, E. Jeannesson, J.-B. Marteau, A. Samara, B. Marie, M. Pfister, and S. Visvikis-Siest Transcription Factor and Drug-Metabolizing Enzyme Gene Expression in Lymphocytes from Healthy Human Subjects Drug Metab. Dispos., January 1, 2008; 36(1): 182 - 189. [Abstract] [Full Text] [PDF]

				G. Ling, Y. Wei, and X. Ding Transcriptional Regulation of Human CYP2A13 Expression in the Respiratory Tract by CCAAT/Enhancer Binding Protein and Epigenetic Modulation Mol. Pharmacol., March 1, 2007; 71(3): 807 - 816. [Abstract] [Full Text] [PDF]

				M. Itoh, M. Nakajima, E. Higashi, R. Yoshida, K. Nagata, Y. Yamazoe, and T. Yokoi Induction of Human CYP2A6 Is Mediated by the Pregnane X Receptor with Peroxisome Proliferator-Activated Receptor-{gamma} Coactivator 1{alpha} J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 693 - 702. [Abstract] [Full Text] [PDF]

				S. Kawashima, K. Kobayashi, K. Takama, T. Higuchi, T. Furihata, M. Hosokawa, and K. Chiba INVOLVEMENT OF HEPATOCYTE NUCLEAR FACTOR 4{alpha} IN THE DIFFERENT EXPRESSION LEVEL BETWEEN CYP2C9 AND CYP2C19 IN THE HUMAN LIVER Drug Metab. Dispos., June 1, 2006; 34(6): 1012 - 1018. [Abstract] [Full Text] [PDF]